1. Home
  2. EXLS vs NUVL Comparison

EXLS vs NUVL Comparison

Compare EXLS & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ExlService Holdings Inc.

EXLS

ExlService Holdings Inc.

HOLD

Current Price

$41.31

Market Cap

6.5B

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$104.31

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXLS
NUVL
Founded
1999
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
7.1B
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
EXLS
NUVL
Price
$41.31
$104.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
14
Target Price
$54.50
$134.29
AVG Volume (30 Days)
1.1M
828.0K
Earning Date
10-28-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
29.94
N/A
EPS
1.48
N/A
Revenue
$2,026,490,000.00
N/A
Revenue This Year
$15.27
N/A
Revenue Next Year
$11.33
N/A
P/E Ratio
$28.13
N/A
Revenue Growth
14.43
N/A
52 Week Low
$37.30
$55.54
52 Week High
$52.43
$112.88

Technical Indicators

Market Signals
Indicator
EXLS
NUVL
Relative Strength Index (RSI) 58.20 51.80
Support Level $39.84 $103.52
Resistance Level $42.03 $107.99
Average True Range (ATR) 0.72 3.17
MACD 0.23 -0.94
Stochastic Oscillator 72.48 10.02

Price Performance

Historical Comparison
EXLS
NUVL

About EXLS ExlService Holdings Inc.

ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage the company's deep expertise in analytics, AI, ML, and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging Business, and Analytics . The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: